Used in research for treating metabolic disorders, JD-5037 acts as a cannabinoid receptor 1 (CB1) inverse agonist. It helps regulate appetite and improve insulin sensitivity, making it a candidate for studying obesity and type 2 diabetes. Due to its peripheral restriction, it minimizes central nervous system side effects, which were a concern with earlier CB1 antagonists. Studies show it can reduce food intake, body weight, and improve glucose tolerance in animal models. It is not used clinically and remains a tool compound for understanding metabolic disease pathways.